title: Ð­ÐºÑÐ¿ÑÐµÑÑÐ¸Ñ Ð³ÐµÐ½Ð° FABP4, ÐºÐ¾Ð´Ð¸ÑÑÑÑÐµÐ³Ð¾ Ð±ÐµÐ»Ð¾Ðº, ÑÑÐ°Ð½ÑÐ¿Ð¾ÑÑÐ¸ÑÑÑÑÐ¸Ð¹ Ð¶Ð¸ÑÐ½ÑÐµ ÐºÐ¸ÑÐ»Ð¾ÑÑ, Ð² Ð¶Ð¸ÑÐ¾Ð²Ð¾Ð¹ ÑÐºÐ°Ð½Ð¸ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÑÐ°Ñ Ð°ÑÐ½ÑÐ¼ Ð´Ð¸Ð°Ð±ÐµÑÐ¾Ð¼ 2 ÑÐ¸Ð¿Ð°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Expression of the FABP4 gene encoding a fatty acid transport protein in adipose tissue from patients with type 2 diabetes mellitus
Creators: name: Ð¡Ð°Ð¿Ð¾Ð¶Ð½Ð¸ÐºÐ¾Ð²Ð°, ÐÐ½ÑÐ¾Ð½Ð¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: FABP4
ÑÐ°Ñ Ð°ÑÐ½ÑÐ¹ Ð´Ð¸Ð°Ð±ÐµÑ 2 ÑÐ¸Ð¿Ð°
Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸Ðµ
Ð¶Ð¸ÑÐ¾Ð²Ð°Ñ ÑÐºÐ°Ð½Ñ
Ð¼ÐµÑÐ°Ð±Ð¾Ð»Ð¸Ð·Ð¼
Ð°Ð´Ð¸Ð¿Ð¾ÑÐ¸ÑÐ¾ÐºÐ¸Ð½Ñ
type 2 diabetes
obesity
adipose tissue
metabolism
adipocytokines

description: ÐÐ°Ð½Ð½Ð¾Ðµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ðµ Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð¾ Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ Ð¾ÑÐ¾Ð±ÐµÐ½Ð½Ð¾ÑÑÐµÐ¹ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð° FABP4 Ð² ÐÐÐ¢ Ð¸ ÐÐÐ¢ Ð¿ÑÐ¸ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸Ð¸ Ð¸ ÑÐ°ÑÐ°ÑÐ½Ð¾Ð¼ Ð´Ð¸Ð°Ð±ÐµÑÐµ 2 ÑÐ¸Ð¿Ð°. Ð ÑÐ¾Ð´Ðµ ÑÐ°Ð±Ð¾ÑÑ Ð½ÐµÐ¾Ð±ÑÐ¾Ð´Ð¸Ð¼Ð¾ Ð±ÑÐ» ÑÐ¾Ð·Ð´Ð°Ð½ Ð±Ð°Ð½Ðº ÐºÐÐÐ ÐÐÐ¢ Ð¸ ÐÐÐ¢ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸ÐµÐ¼ Ñ/Ð±ÐµÐ· Ð¡Ð2 (N=43, Ð¸Ð· Ð½Ð¸Ñ 21 - Ñ Ð¡Ð2) Ð¸ Ð»Ð¸Ñ Ð±ÐµÐ· Ð´Ð°Ð½Ð½ÑÑ Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸Ð¹ (ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð°Ñ Ð³ÑÑÐ¿Ð¿Ð°, N=15) Ð¸ Ð±ÑÐ» Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½ ÑÑÐ°Ð²Ð½Ð¸ÑÐµÐ»ÑÐ½ÑÐ¹ Ð°Ð½Ð°Ð»Ð¸Ð· ÑÐ¾Ð´ÐµÑÐ¶Ð°Ð½Ð¸Ñ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð° FABP4 Ð² ÑÑÐ¸Ñ Ð¾Ð±ÑÐ°Ð·ÑÐ°Ñ. Ð­ÑÐ¾ Ð¿ÑÐµÐ´Ð¿Ð¾Ð»Ð°Ð³Ð°Ð»Ð¾ Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ ÑÐ¾ÑÐ°Ð»ÑÐ½Ð¾Ð¹ Ð ÐÐ Ñ Ð¿Ð¾ÑÐ»ÐµÐ´ÑÑÑÐµÐ¹ Ð¿Ð¾ÑÑÐ°Ð½Ð¾Ð²ÐºÐ¾Ð¹ ÑÐµÐ°ÐºÑÐ¸Ð¸ Ð¾Ð±ÑÐ°ÑÐ½Ð¾Ð¹ ÑÑÐ°Ð½ÑÐºÑÐ¸Ð¿ÑÐ¸Ð¸, Ð¾ÑÐµÐ½ÐºÑ Ð¾ÑÐ½Ð¾ÑÐ¸ÑÐµÐ»ÑÐ½Ð¾Ð³Ð¾ ÑÑÐ¾Ð²Ð½Ñ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð° FABP4 Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ ÐÐ¦Ð  Ð² ÑÐµÐ°Ð»ÑÐ½Ð¾Ð¼ Ð²ÑÐµÐ¼ÐµÐ½Ð¸ Ð¸ ÑÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÐ¸Ð¹ Ð°Ð½Ð°Ð»Ð¸Ð· Ð´Ð°Ð½Ð½ÑÑ. ÐÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ ÑÑÐ¾Ð²ÐµÐ½Ñ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð° ÑÐ½Ð¸Ð¶ÐµÐ½ Ð² ÐÐÐ¢ Ð¸ ÐÐÐ¢ Ð¿ÑÐ¸ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸Ð¸, Ð² Ð½Ðµ Ð·Ð°Ð²Ð¸ÑÐ¸Ð¼Ð¾ÑÑÐ¸ Ð½Ð°Ð»Ð¸ÑÐ¸Ñ Ð¡Ð2 (p&lt;0.01). ÐÑÐ»Ð° Ð²ÑÑÐ²Ð»ÐµÐ½Ð° Ð¾ÑÑÐ¸ÑÐ°ÑÐµÐ»ÑÐ½Ð°Ñ ÐºÐ¾ÑÑÐµÐ»ÑÑÐ¸Ñ Ð¼ÐµÐ¶Ð´Ñ Ð¿Ð¾ÐºÐ°Ð·Ð°ÑÐµÐ»ÐµÐ¼ ÐÐÐ¢ Ð¸ ÑÑÐ¾Ð²Ð½ÐµÐ¼ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð° Ð² Ð¶Ð¸ÑÐ¾Ð²Ð¾Ð¹ ÑÐºÐ°Ð½Ð¸, ÐºÐ¾ÑÐ¾ÑÐ°Ñ ÑÐ¾ÑÑÐ°Ð½ÑÐ»Ð°ÑÑ Ñ ÑÑÑÑÐ¾Ð¼ Ð¿Ð¾Ð¿ÑÐ°Ð²ÐºÐ¸ Ð½Ð° Ð¿Ð¾Ð» Ð¸ Ð²Ð¾Ð·ÑÐ°ÑÑ (Ð´Ð»Ñ ÐÐÐ¢: r = -0.327, p=0.016; Ð´Ð»Ñ ÐÐÐ¢: r = -0.304, p=0.024). ÐÑÐ¸ ÑÑÐ¾Ð¼ Ð±ÑÐ»Ð° Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð° Ð¿Ð¾Ð»Ð¾Ð¶Ð¸ÑÐµÐ»ÑÐ½Ð°Ñ ÐºÐ¾ÑÑÐµÐ»ÑÑÐ¸Ñ Ð´Ð»Ñ ÑÑÐ¾Ð²Ð½Ñ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð° FABP4 Ð² ÐÐÐ¢ Ð¸ ÐÐÐ¢ (Î²=0.858, p=0.000). ÐÑÐ»Ð° Ð²ÑÑÐ²Ð»ÐµÐ½Ð° Ð¾ÑÑÐ¸ÑÐ°ÑÐµÐ»ÑÐ½Ð°Ñ ÐºÐ¾ÑÑÐµÐ»ÑÑÐ¸Ñ ÑÑÐ¾Ð²Ð½Ñ Ð¼Ð ÐÐ Ð³ÐµÐ½Ð° FABP4 Ð² ÐÐÐ¢ Ñ Ð¿Ð¾ÐºÐ°Ð·Ð°ÑÐµÐ»ÐµÐ¼ Ð³Ð»Ð¸ÐºÐ¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð³ÐµÐ¼Ð¾Ð³Ð»Ð¾Ð±Ð¸Ð½Ð° (Ñ Ð¿Ð¾Ð¿ÑÐ°Ð²ÐºÐ¾Ð¹ Ð½Ð° Ð¿Ð¾Ð», Ð²Ð¾Ð·ÑÐ°ÑÑ Ð¸ ÐÐÐ¢ Î²=-0.893, p=0.009). ÐÐ°Ð»ÑÐ½ÐµÐ¹ÑÐ¸Ðµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ, Ð½Ð°Ð¿ÑÐ°Ð²Ð»ÐµÐ½Ð½ÑÐµ Ð½Ð° ÑÑÑÐ°Ð½Ð¾Ð²Ð»ÐµÐ½Ð¸Ðµ Ð¸ ÑÐµÐ³ÑÐ»ÑÑÐ¸Ñ Ð¼ÐµÑÐ°Ð½Ð¸Ð·Ð¼Ð° ÑÐµÐºÑÐµÑÐ¸Ð¸ FABP4 Ð¿ÑÐ¸ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÑ Ð¼ÐµÑÐ°Ð±Ð¾Ð»Ð¸ÑÐµÑÐºÐ¸Ñ Ð½Ð°ÑÑÑÐµÐ½Ð¸ÑÑ Ð¸ Ð¾Ð¶Ð¸ÑÐµÐ½Ð¸Ð¸, Ð¼Ð¾Ð³ÑÑ Ð¿Ð¾ÑÐ»ÑÐ¶Ð¸ÑÑ Ð¾ÑÐ½Ð¾Ð²Ð¾Ð¹ Ð´Ð»Ñ Ð±Ð¾Ð»ÐµÐµ Ð±ÑÑÑÑÐ¾Ð¹ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ¸ Ð¸ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾Ð³Ð¾ Ð»ÐµÑÐµÐ½Ð¸Ñ Ð¡Ð2 Ð¸ Ð°ÑÑÐ¾ÑÐ¸Ð¸ÑÐ¾Ð²Ð°Ð½Ð½ÑÑ Ñ Ð½Ð¸Ð¼ Ð¾ÑÐ»Ð¾Ð¶Ð½ÐµÐ½Ð¸Ð¹.
description: The given work is devoted to the study of the features of the expression of the FABP4 gene in the SAT and VAT in patients with obesity and type 2 diabetes mellitus. In the course of the work, a cDNA bank was created for SAT and VAT of obese patients with/without DM2 (N=43, 21 of them with DM2) and persons without these pathologies (control group, N=15) and a comparative analysis of the mRNA content of the FABP4 gene in these samples was carried out. This involved the isolation of total RNA followed by a reverse transcription reaction, an assessment of the relative mRNA level of the FABP4 gene by real-time PCR and statistical data analysis. It was shown that the mRNA level of the gene was reduced in the SAT and VAT in obesity, regardless of the presence of DM2 (p&lt;0.01). A negative correlation was detected between BMI index and the level of mRNA of the gene in adipose tissue, which was maintained considering the correction for gender and age (for SAT: r = -0.327, p=0.016; for VAT: r = -0.304, p=0.024). At the same time, a positive correlation (Î²=0.858, p=0.000) was shown for the mRNA level of the FABP4 gene in the SAT and VAT. A negative correlation was found between the mRNA level of the FABP4 gene in the pancreas and the glycated hemoglobin index (adjusted for gender, age and BMI Î²=-0.893, p=0.009) Further studies aimed at establishing and regulating the mechanism of FABP4 secretion in various metabolic disorders and obesity can serve as a basis for faster diagnosis and effective treatment of DM2 and its associated complications.